A mulTi-center, Randomized, doUble-bliNded, Placebo-controlled Dose-escalating Study of the Effects of K201 on the RestorAtion of Sinus Rhythm in Subjects With Symptomatic Atrial Fibrillation of Recent Onset.
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2016
At a glance
- Drugs JTV 519 (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions; Therapeutic Use
- Acronyms TUNDRA-AF
- Sponsors Sequel Pharmaceuticals
- 13 May 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 01 Mar 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 01 Mar 2011 Actual initiation date (February 2011) added as reported by ClinicalTrials.gov.